New pill aims to break the cycle of repeat c. diff infections
NCT ID NCT07513285
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an oral drug called ibezapolstat in 20 people who have had three or more C. diff infections in the past year. The goal is to see if the drug can cure the current infection and reduce the chance of it coming back. Participants will take the drug twice a day for 14 days, and researchers will track cure rates and changes in gut bacteria.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ibezapolstat (ACX-362E)
- What this could lead to
- If successful, this could provide a new treatment option for people with stubborn, repeat C. diff infections, potentially lowering the chance of future episodes.
- What could go wrong
- This is a small, early-phase trial with only 20 participants and no comparison group, so results may not apply broadly. The drug may not work as hoped or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIUM DIFFICILE INFECTION RECURRENCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe why poop transplants work for gut infections
- Poop pills aim to break the cycle of recurrent c. diff
- Poop pills? no, stool transplants aim to cure recurrent c. diff
- New way to deliver c. diff treatment: through a colonoscopy
- 4,000-Patient study to reveal if poop transplants really work Long-Term
- Promising c. diff drug trial halted after just 3 patients